Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Posts Tagged ‘sequence enrichment’

Thursday, February 18th, 2010

RainDance and Life Technologies Co-Market Microdroplet PCR-Based Enrichment for Targeted Resequencing on the SOLiD System

rdt-702290

LEXINGTON, MASSACHUSETTS, U.S.A., February 18, 2010 – RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for human health and disease research, and Applied Biosystems, part of Life Technologies Corporation (NASDAQ: LIFE), announced today they have entered into a strategic agreement to co-market the first solution that combines microdroplet PCR-based sequence enrichment with next-generation sequencing.

Under the terms of the agreement, the companies will co-market RainDance’s RDT 1000 Sequence Enrichment Solution with Applied Biosystems SOLiD™ System, a next-generation high-throughput DNA analysis platform. The integration of the two technologies will enable researchers to perform highly efficient, large-scale targeted sequencing studies with the superior quality and accuracy of results associated with PCR-based DNA amplification. In addition, the companies will continue to collaborate on the application of RainDance products in the SOLiD System sequencing workflow.

“PCR is the gold standard for sequence enrichment and we’re pleased to provide a microdroplet PCR-based solution that works seamlessly with the SOLiD System,” said Christopher McNary, Chief Commercial Officer, RainDance Technologies. “Now researchers can perform high-resolution analysis of genetic variation by combining the high degree of sample uniformity and reduced selection bias of PCR-based enrichment with the greater accuracy, efficiency, and throughput of the SOLiD platform. Using RainDance Technologies, researchers will be able to detect substantially higher numbers of variants in the targeted sequences than have been demonstrated with alternative approaches using less precise capture methods,” McNary said.

“By partnering with RainDance Technologies, we can provide scientists with a sequence enrichment solution that leverages the quality and accuracy of PCR, enabling studies of hundreds to thousands of samples — with the high degree of accuracy associated with SOLiD System technology,” said Shaf Yousaf, President, Genomic Analysis, Life Technologies.

TGEN Validates RainDance-SOLiD Solution

The Translational Genomics Research Institute (TGEN) of Phoenix, Arizona, was among the first to couple the RainDance Sequence Enrichment Solution with ABI’s SOLiD sequencing technology. TGEN utilized the integrated workflow to identify root cause mutations in disease candidate genes and pathways.

“The RainDance and SOLiD technology worked smoothly and offered superb coverage and accuracy,” said John Carpten, Ph.D., Senior Investigator and Director, Integrated Cancer Genomics Division, TGEN. Dr. Carpten’s work is focused in search of germline variants associated with cancer risk, and somatic mutations occurring in both solid tumors and hematological malignancies.

“We have successfully interrogated specific regions of the genome and identified novel somatic mutations in normal/tumor pairs within a relatively short period of time. We are looking forward to expanding our use of both the RainDance and SOLiD platforms to other large-scale resequencing projects,” said Dr. Carpten. “Our hope is that these tools will allow us to efficiently interrogate specific regions of the cancer genome, which in turn will ultimately lead to an increased understanding of cancer development. Our ultimate hope is translation of these findings for improved patient care.”

About RainDance Technologies, Inc.
RainDance’s proprietary technology platform delivers exquisite sensitivity and data quality that inspires scientists, researchers and clinicians to rethink the way they design experiments, approach discovery, or conduct clinical diagnostics. The core RainStorm™ technology empowers customers to conduct de novo science in an ultra-high throughput, simple, flexible, and low-cost manner. RainDance’s commercial products include instruments and high-value consumables and reagents for sequence enrichment for next-generation sequencing, ultra-deep sequencing, and methylation analysis. RainDance sells directly in the U.S. and in Europe, and is building distribution networks in Europe and Asia-Pacific. RainDance Technologies has approximately 70 employees worldwide. For more information, please visit www.raindancetech.com.

RainStorm is a trademark of RainDance Technologies, Inc.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.
Copyright 2009. Life Technologies Corporation. All rights reserved. AB (Design), and Applied Biosystems are registered trademarks and SOLiD are trademarks of Life Technologies or its subsidiaries in the United States and/or certain other countries

Tags: Life Technologies, Microdroplet PCR-Based Enrichment, o RainDance Technologies, sequence enrichment, single-cell analysis, SOLiD System, targeted resequencing
Posted in Biosciences |

Wednesday, February 3rd, 2010

RainDance Technologies Appoints S. Roopom Banerjee as President and Chief Executive Officer

Disruptive platform technology enables greater speed, sensitivity, and simplicity for single-cell analysis to accelerate breakthroughs in human health and disease research and diagnostics

LEXINGTON, MASSACHUSETTS, U.S.A – February 3, 2010 – RainDance Technologies Inc., the leader in sequence enrichment and single-cell analysis, today announced that the Board of Directors has appointed Sirshendu Roopom Banerjee as President and Chief Executive Officer. RainDance Technologies provides innovative microdroplet-based solutions that accelerate research and development for human healthcare and industrial markets. The company provides resolution of molecular, biological, and physiological events from large population samples to unprecedented single-cell analysis, all inside a contained microenvironment that enables quantification, single-molecule sensitivity, and preserves sample integrity with no bias or contamination.

About the appointment, RainDance Director and Managing Partner of Mohr Davidow Ventures Bill Ericson said, “Roopom brings a depth of knowledge and is highly respected in the life science tools and diagnostics industry. Roopom’s leadership will enable us to further accelerate the momentum built over the last few years in the adoption of our highly innovative RainStorm™ technology, as well as sharpen our focus on new product and technology opportunities in the fields of sequence enrichment and single-cell analysis.”

Most recently, Mr. Banerjee was a Director of Healthcare Investment Banking at Leerink Swann, where he led the Life Science Tools and Diagnostics sector. Previously, Mr. Banerjee was with McKinsey and Goldman Sachs advising Fortune 500 healthcare companies globally on corporate and growth strategy, product development and launch strategy, international expansion, and mergers and acquisitions. Mr. Banerjee has successfully completed over 50 transactions, including private placements, IPOs, Followons, PIPE/RDs, and fixed income as well as mergers and acquisitions.

Earlier in his career, Mr. Banerjee worked at the Dana Farber Cancer Institute, the Whitehead Institute/M.I.T. Human Genome Project, and at the Massachusetts General Hospital Cancer Center. Mr. Banerjee holds an M.P.P. from the Kennedy School of Government at Harvard University and dual B.S. degrees in Biology and Economics from M.I.T., where he was elected a Howard Hughes Medical Institute Scholar.

“This is a significant time to join RainDance, with the company experiencing breakthrough sales growth. We are seeing strong customer demand for our novel products in sequence enrichment, such as rare variant analysis, as well as future applications in methylation and ultra-deep sequencing. RainDance is truly platform-agnostic and capitalizing on the explosive growth across next-generation sequencing,” said Banerjee. “Beyond sequence enrichment, we have demonstrated unique capabilities in digital PCR as well as protein, antibody, and single-cell applications. I am excited to be joining a high-caliber team with a proven track record of execution in these areas.”
Christopher McNary, who has served RainDance as CEO since November 2007, will join Mr. Banerjee on the senior executive team as Chief Commercial Officer and will focus on moving the company into high-growth commercialization. Mike Hunkapiller, General Partner at Alloy Ventures and Director at RainDance said, “Chris has brought strong leadership and operating experience to guide RainDance from technology-stage through commercial launch of our flagship RDT 1000 product. We are excited that Chris is turning his focus to leading the commercial charge for RainDance. RainDance is uniquely poised to unlock large latent markets and address unmet customer needs for single-cell analysis.”

About RainDance Technologies

RainDance Technologies’ proprietary technology platform delivers exquisite sensitivity and data quality that inspires scientists, researchers, and clinicians to rethink the way they design experiments, approach discovery, or conduct clinical diagnostics. The core RainStorm technology empowers customers to conduct de novo science in an ultra-high throughput, simple, flexible, and low-cost manner. RainDance’s commercial products include instruments and high-value consumables and reagents for sequence enrichment for next-generation sequencing, ultra-deep sequencing, and methylation analysis. RainDance sells directly in the U.S. and in Europe, and is building distribution networks in Europe and Asia-Pacific. RainDance Technologies, with headquarters in Lexington, Massachusetts, and a European sales office in the United Kingdom, has approximately 70 employees worldwide. For more information, please visit www.raindancetech.com.

RainStorm is a trademark of RainDance Technologies, Inc.

# # #

Tags: Alloy Ventures, microdroplet PCR, Mohr Davidow Ventures, RainDance Technologies, sequence enrichment, single-cell analysis, Sirshendu Roopom Banerjee, targeted sequencing
Posted in Biosciences |

Tuesday, January 19th, 2010

RainDance Technologies Primer Library Design – FAQs

RainDance Technologies has published an FAQ that helps researchers design primer libraries for their targeted sequencing studies. Custom-order libraries for the company’s RDT 1000 system allow scientists to define libraries to enrich for loci of interest using RainDance’s Sequence Enrichment Solution. PCR primers will be designed by RainDance to maximize specificity and yield using RainStorm(TM) droplet-based PCR.

The FAQ covers topics such as:

What is the average primer design coverage of target regions from RainDance’s primer design?
Do different sequencing platforms require different primer design parameters?
What kind of gene or genomic region identifiers should I use?

To download the FAQ, visit: http://www.raindancetech.com/documents/Primer_Library_FAQ_2010.pdf

About RainDance Technologies, Inc.

RainDance Technologies, Inc., is a provider of innovative microdroplet-based solutions for single-cell analyses that will accelerate human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm™ technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application focuses on the targeted sequencing of the human genome – one of the fastest-growing segments of the $1 billion DNA sequencing market. This application enables the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

RainStorm is a trademark of RainDance Technologies, Inc.

# # #

Public Relations contact, Boston: Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Tags: FAQ, microdroplet PCR, Nature Biotechnology, RainDance Technologies, sequence enrichment, targeted sequencing
Posted in Biosciences |

Monday, November 2nd, 2009

Paper Finds Microdroplet PCR Enrichment Is Ideal Targeted Sequencing Solution For Large-Scale Population Studies

rdt-702290 LEXINGTON, MASSACHUSETTS, U.S.A. – November 2, 2009 – Data generated using microdroplet PCR technology as an enrichment method is particularly well suited for performing sequence-based association studies, according to a paper published today by researchers at the Scripps Translational Science Institute, the University of California, San Diego School of Medicine, and RainDance Technologies, Inc.

The study, led by Kelly A. Frazer, Ph.D., Professor of Pediatrics and Chief, Division of Genome Information Sciences, UC San Diego Department of Pediatrics, evaluated microdroplet PCR’s advantages in performing sequence enrichment for targeted sequencing over the gold-standard traditional PCR approach. “These benefits translated into a much higher efficiency of sequencing and a much more cost-effective way to do population studies,” Frazer said, in commenting about the paper.

Entitled “Microdroplet-based PCR Enrichment for Large-Scale Targeted Sequencing,” the paper was published today on Nature Biotechnology’s Web site at Microdroplet-based PCR enrichment for large-scale targeted sequencing : Abstract : Nature Biotechnology (www.nature.com/nbt/journal/vaop/ncurrent/abs/nbt.1583.html) and will appear in the November issue of the magazine.

“I believe this new technology will be used to study the basic underpinnings of diseases and to understand their root causes,” said Eric J. Topol, M.D., Director of the Scripps Translational Science Institute and a co-author. “For instance, we’re now using it to understand the causes of anorexia nervosa. We also can use the technology to comprehend a disease’s response to a therapy or to determine a drug’s side effects. We even can employ it to study the healthy aging process. These are all applications for microdroplet PCR that will help us understand the vital aspects of human health and disease,” said Dr. Topol, in commenting on the paper.

The paper said that to efficiently perform population-based sequencing studies using next-generation sequencing platforms, it is important to be able to simultaneously examine large numbers of targeted sequences. “These results indicate that even when simultaneously amplifying 3,976 targeted sequences, microdroplet PCR generates a high ratio of target sequence to background sequence,” the authors said. The study concluded that data quality is independent of the number of amplicons. A path to scale to 20,000 amplicons while maintaining high performance was also demonstrated.

The paper’s authors said the microdroplet PCR process proved to be extremely efficient, with more than 99.6% of all amplicons being successful and with highly reproducible amplification of targeted sequences between samples. The data also showed that equivalently accurate SNP calling can be performed using microdroplet PCR whether the DNA is unamplified or whole-genome amplified from nanogram quantities. The allelic bias error rate of approximately 0.1% resulted in few known variants to be incorrectly called, further attesting to the robustness of the process.

“We were impressed with how well the technology worked,” said Dr. Frazer. “Compared to other types of sequence enrichment, we were able to generate greater uniform coverage of targeted sequences. In addition, the problems we typically encounter with standard PCR, such as difficult primer design and high allelic bias, were not observed with the microdroplet-based PCR workflow.”

“Efficient targeted sequencing will be critical as researchers study genetic variation in large populations to determine the causes of cancer and other complex diseases,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “This study confirms that our innovative RDT 1000 microdroplet-based platform is able to detect substantially higher numbers of variants in the targeted sequences than either solution-based hybridization or molecular inversion probes. This platform provides scientists with an exciting and highly effective new technology that accelerates research into the causes of these devastating diseases,” said McNary.

To view the paper, visit Microdroplet-based PCR enrichment for large-scale targeted sequencing : Abstract : Nature Biotechnology (www.nature.com/nbt/journal/vaop/ncurrent/abs/nbt.1583.html) or see the November 2009 issue of Nature Biotechnology: “Microdroplet-based PCR Enrichment for Large-Scale Targeted Sequencing.” Authors: Ryan Tewhey^1,2, Jason Warner³, Masakazu Nakano^1,4, Brian Libby³, Martina Medkova³, Patricia David³, Steve Kotsopoulos³, Michael Samuels³, J. Brian Hutchinson³, Jonathan W. Larson³, Eric J. Topol¹, Michael P. Weiner³, Olivier Harismendy^1,4, Jeff Olson³, Darren R. Link³, and Kelly A. Frazer^1,4. DOI:10.1038/nbt.1583.

About RainDance Technologies, Inc.

RainDance�s initial application focuses on the targeted sequencing of the human genome – one of the fastest-growing segments of the $1 billion DNA sequencing market. This application enables the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

RainStorm is a trademark of RainDance Technologies, Inc.

¹Scripps Genomic Medicine, Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, California, U.S.A.
²Division of Biological Sciences, University of California at San Diego, La Jolla, California, U.S.A.
³RainDance Technologies, Lexington, Massachusetts, U.S.A.
⁴Present address: Moores UCSD Cancer Center, La Jolla, California, U.S.A.

# # #

Public Relations contact, Boston: Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Tags: Eric Topol, Kelly Frazer, microdroplet PCR, Nature Biotechnology, RainDance Technologies, sequence enrichment, targeted sequencing
Posted in Biosciences, Technology |

Thursday, October 22nd, 2009

RainDance Extends Sequence Enrichment Solution Capabilities With Methyl-Seq and Ultra-Deep Resequencing Applications

rdt-702290

HONOLULU, HAWAII, U.S.A., October 22, 2009 — RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for human health and disease research, announced today it will extend the capabilities of its Sequence Enrichment Solution by offering Methyl-Seq and Ultra-Deep Resequencing applications.

In a presentation at the 59th Annual Meeting of the American Society of Human Genetics, the company said these enhancements represent a significant expansion of the RainDance technology platform’s capabilities. They will enable researchers to use their RDT 1000 instruments for epigenomic and ultra-deep resequencing studies that can accurately characterize the molecular basis for cancer and other destructive diseases.

“Methyl-Seq and Ultra-Deep Resequencing will provide exciting new tools to our customers’ research methodologies,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “Now scientists can apply our Sequence Enrichment Solution to gain better understanding of how disease cells differ from normal cells, enhancing their understanding of the origins and pathways of complex diseases.”

Methyl-Seq Allows Use of PCR-Based Enrichment and Next-Generation Sequencing for Higher-Resolution Epigenomic Studies

RainDance said its Methyl-Seq application will provide scientists with new capabilities for epigenomics research, a field recognized in a National Institutes of Health Roadmap as having exceptionally high potential to transform biomedical research. The study of epigenomics explores how factors such as environment can change gene expression and gene activity over time in a manner that heightens susceptibility to disease.

The Methyl-Seq application will allow researchers, for the first time, to combine PCR-based sequence enrichment with the power of next-generation sequencing platforms to perform epigenomic studies at significantly higher resolution. By studying methylation patterns with single-base resolution across targeted regions of the genome, researchers can get a better understanding of epigenomic variation and can discover opportunities to develop new treatments for cancer and other complex diseases.

“Methyl-Seq enables the targeted amplification and next-generation sequencing of bisulfite-converted DNA for the identification of methylated bases in the genome with greater accuracy and quality of data,” said McNary.

Ultra-Deep Resequencing Enables PCR-Based Enrichment to Accurately Characterize Variance in Heterogeneous Samples

RainDance’s Ultra-Deep Resequencing application enables the use of the company’s PCR-based Sequence Enrichment Solution to accurately characterize rare variants in highly heterogeneous samples, such as those found in cancer tumors. Studies suggest that rare genetic variants may play significant roles in tumorigenesis, pathogenesis, and disease progression. Previously, ultra-deep resequencing of heterogeneous samples with standard PCR approaches has been difficult because of the loss of accurate DNA representation.

“The unique compartmentalization capability of our RainStorm microdroplet-based technology provides highly efficient amplification of all sequence variants in the sample,” McNary said. “This ensures that accurate representation and a high depth of coverage are maintained for ultra-low frequency variants.”

Both the Methyl-Seq and Ultra-Deep Resequencing applications will be commercially available during the first half of 2010. They will utilize the RDT 1000 system’s proven consumables and reagents.

“The capabilities of these new applications, plus the expanded-content DNA primer libraries and WGA sample protocols announced last month, make the RDT 1000 a highly flexible genomic research platform that easily integrates with any next-generation sequencing workflow,” said McNary. “Both the Methyl-Seq and Ultra-Deep Resequencing applications are simple to use and integrate seamlessly with our Sequence Enrichment Solution. Our applications will help researchers rethink their approaches to discovery as they unlock the cures for the world’s most devastating diseases,” he said.

About RainDance Technologies, Inc.

RainDance Technologies, Inc., is a provider of innovative microdroplet-based solutions for single-cell analyses that will accelerate human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm^TM technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application focuses on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application enables the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

RainStorm is a trademark of RainDance Technologies, Inc.

# # #

Public Relations contact, Boston: Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Tags: epigenomics, RainDance, RainDance Technologies, sequence enrichment, ultra-deep sequencing
Posted in Biosciences, Technology |

Tuesday, May 26th, 2009

RainDance Technologies Announces First European Order for Sequence Enrichment Solution to ATLAS Biolabs

VIENNA, AUSTRIA, May 26, 2009 – RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced it has received the first European order for its Sequence Enrichment Solution from ATLAS Biolabs GmbH of Berlin, Germany, a leading genomic services provider.

In an announcement at the European Society of Human Genetics (ESHG) Conference 2009, the company said ATLAS Biolabs’ purchase includes the RDT 1000 system, PCR primer libraries, consumables kits, and training services.

“ATLAS Biolabs is a renowned genomic services provider with an esteemed scientific team that is highly respected in the European research community,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “We look forward to supporting their requirements with a solution that can dramatically enhance their genomic research services portfolio.”

McNary said the sale represents a key addition to the company’s global service provider network. “With our Sequence Enrichment Solution in place at ATLAS Biolabs, European researchers will have immediate access to our technology. It will enable scientists to perform high-resolution analysis of genetic variation between individuals within populations at a level unmatched by current methodologies,” he said.

“Our customers now are exploring the contribution of rare variants in their study of disease and are adopting targeted genomic sequencing methods to study large populations in this context. RainDance’s massively parallel microdroplet PCR-based solution for sequence enrichment is superior to all others available in the market because it is less prone to the selection bias associated with targeted sequencing,” said Dr. Peter Nürnberg, Co-Founder and Chief Executive Officer, ATLAS Biolabs. “Using the RainDance technology, we can amplify up to 4000 amplicons in a single PCR process with essentially no allelic amplification bias and a near 100% success rate of PCR primer pairs.”

Nürnberg said ATLAS Biolabs is discussing the RainDance Sequence Enrichment Solution with key customers and will invite them to perform proof-of-principle experiments once the instrument is installed. “We are pleased to be the first in Europe to offer this innovative approach and will work with RainDance to explore additional applications for their promising new technology.”

RainDance will immediately begin designing custom DNA primer libraries for ATLAS Biolabs’ customers and anticipates shipping the RDT 1000 system by July 2009.

“The first sale of our Sequence Enrichment Solution in Europe is a major step in our company’s growth,” said McNary. “Our technology is generating considerable interest in the region, and we anticipate announcing additional sales to leading European genomic and medical research centers in the coming weeks.”

For sales information, contact Patrick Kelly, Director of Sales – European Region, RainDance Technologies, at kellyp@raindancetech.com or +44-786-3200-242.

About RainDance Technologies, Inc.

RainDance Technologies, Inc., based in Lexington, Massachusetts, U.S.A., is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application focuses on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

About ATLAS Biolabs

ATLAS Biolabs GmbH is a leading provider of microarray-based genomic services such as genome-wide gene expression and SNP analyses, CGH analyses, and diagnostic services for registered doctors and hospitals, as well as for pharmaceutical, biotechnological, and diagnostic enterprises. The company is based in Berlin and Cologne, Germany.

Tags: ATLAS Biolabs, DNA sequencing, PCR, RainDance Technologies, RDT 1000, sequence enrichment, targeted sequencing
Posted in Biosciences |

Tuesday, May 5th, 2009

RainDance Technologies CEO to Present at Transformational Tools Panel During 2009 BIO International Convention

LEXINGTON, MASSACHUSETTS, U.S.A., May 5, 2009 — Christopher McNary, RainDance Technologies President and Chief Executive Officer, will discuss the impact of new transformational tools shaping life sciences research during a panel session at the 2009 BIO International Convention in Atlanta on May 20, 2009.

The session, Transformational Tools: How New Research Technologies Are Changing the Rules of the Game, will review how the accessibility and power of these new tools are empowering individual scientists to conduct research that was formerly infeasible, unaffordable, or threatening to the research status quo.

In his remarks, McNary will discuss how exciting new technologies are enabling researchers to rethink the way they design experiments and approach discovery, permitting the achievement of previously unattainable breakthrough science. He will cite that the capabilities of his company’s RainStormTM microdroplet-based technology platform can be applied across a wide range of biomedical research applications. For example, McNary will describe how a researcher can collect a heterogeneous group of cells of interest, such as a cancer sample, break it down into homogeneous collections of primary cells such as tumor and stem cells, capture and interrogate these as single cells, and perform scientific analyses. This capability will help make exciting strides in understanding the fundamental biology of complex disease.

In addition, McNary will explain how the RainStorm platform also is being applied in collaboration with sanofi-aventis to develop game-changing high-throughput screening methodologies for drug discovery. This work will accelerate the discovery process by enabling pharmaceutical companies to make better and faster decisions about what compounds should be pulled through their development pipelines. McNary will review how these new workflows minimize experimental unknowns, permit simple sample manipulation, and generate accurate measurements at levels unimaginable only a few years ago.

McNary and the other chief executives on the panel also will describe the radical innovations, new perspectives, and diverse disciplines underlying these new technologies, as well as challenges to development and commercialization.

To learn more, visit the RainDance Technologies Website at www.raindancetech.com, or call 781-861-6300.

For more information about the 2009 BIO International Convention, visit http://convention.bio.org/.

About RainDance Technologies, Inc.
RainDance Technologies, Inc., is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

RainStorm is a trademark of RainDance Technologies, Inc.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/
bookmark to del.icio.us

Technorati tags: RainDance Technologies, sequence enrichment, targeted sequencing, RDT 1000, DNA sequencing, PCR, Expression Analysis

Tags: DNA sequencing, Expression Analysis, PCR, RainDance Technologies, RDT 1000, sequence enrichment, targeted sequencing
Posted in Biosciences |

Friday, April 17th, 2009

RainDance Technologies Announces Sale of RDT 1000, Sequence Enrichment Solution to Expression Analysis

LEXINGTON, MASSACHUSETTS, U.S.A., April 17, 2009 – RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the commercial sale of an RDT 1000 and Sequence Enrichment Solution to Expression Analysis, Inc., a leading provider of genomic services for clinical trials and research.

The RainDance solution will enable Expression Analysis to expand its service offerings to provide genomic researchers quality and efficient targeted sequencing on large sample numbers.

“As the market leader in genomic outsourcing for gene expression, genotyping, and resequencing analysis, we enable our service offerings using best-in-class systems. RainDance Technologies is clearly in this class, and we are proud to incorporate their technology to further expand our suite of services and look forward to offering expanded DNA sequencing applications,” said Steve McPhail, President and Chief Executive Officer of Expression Analysis.

The announcement marks the first sale of the RainDance solution to a service provider. The solution consists of an RDT 1000, consumables kits, custom PCR primer libraries, and expert training.

“As a leading genomic service provider, Expression Analysis’ decision to embrace our platform accelerates the ability of researchers to access our sequence enrichment technology,” said Christopher McNary, President and Chief Executive Officer of RainDance Technologies.

The RDT 1000 and Sequence Enrichment Solution utilize RainDance’s breakthrough RainStorm™ microdroplet-based technology platform. The simplicity and speed of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter-volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrichment Solution utilizes a library of PCR primers in droplets, enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance’s solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.

The commercial version of the Sequence Enrichment Solution is now being shipped in North America and will soon be available for shipment to Europe. For more information, contact info@raindancetech.com, call 781-861-6300, or visit the company’s website at http://www.raindancetech.com/.

About RainDance Technologies, Inc.
RainDance Technologies, Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm™ technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit http://www.raindancetech.com/.

RainStorm™ is a trademark of RainDance Technologies, Inc.

About Expression Analysis, Inc.
Expertise Beyond Expression — Providing whole genome to focused set gene expression and genotyping assays, along with sequencing services using RainDance Technologies, Illumina, Affymetrix, and Applied Biosystems. A leading provider of genomic services in clinical trials and research, Expression Analysis offers solutions for challenging specimens such as blood and FFPE tissue specimens as well as nucleic acid isolation and bioinformatic services. The company’s quality system follows CLSI guidelines and their CLIA-registered lab supports GLP compliance.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/
bookmark to del.icio.us

Technorati tags: RainDance Technologies, sequence enrichment, targeted sequencing, RDT 1000, DNA sequencing, PCR, Expression Analysis

Tags: DNA sequencing, Expression Analysis, PCR, RainDance Technologies, RDT 1000, sequence enrichment, targeted sequencing
Posted in Biosciences |

Tuesday, March 31st, 2009

RainDance Technologies to Present Session on Sequence Enrichment Using Innovative Microdroplet-Based Solutions at “Genomics in Business” Conference

MANCHESTER, UK – 31 March, 2009 – RainDance Technologies, Inc. will present a session on sequence enrichment using innovative microdroplet-based solutions at the “Genomics in Business” conference in Amsterdam on 20 April, 2009.

Recent advances in DNA sequencing technologies have improved accuracy and dramatically reduced cost. However, even with the improved efficiency of “second-generation” systems, sequencing thousands of human genomes across various phenotypes is still economically unrealistic. To exploit the full potential of new sequencing techniques, a robust method for isolating biologically relevant genomic loci on the megabase scale will be required.

Analogous to what the massively parallel sequencing technologies have done to improve the efficiency of DNA sequencing, RainDance Technologies has developed a platform to enable the use of PCR for high-throughput amplification of targeted genomic sequences.

In the “Genomics in Business” conference session titled “New High-Throughput Sequencing and Screening Technologies,” Patrick Kelly, Director, European Sales, RainDance Technologies, will explain the application of the company’s new Sequence Enrichment technology.

“The Sequence Enrichment Solution leverages our RainStorm™ technology to manipulate picoliter-volume droplets in disposable chips. We will present the use of this novel method for enrichment of genomic loci with minimal selection bias prior to sequencing, demonstrating the utility of this approach for the routine application of targeted sequencing,” Kelly said.

To learn more about RainDance Technologies, and its revolutionary new RainStorm microdroplet-based technology, attend the session titled “New High-Throughput Sequencing and Screening Technologies” at the “Genomics in Business” conference in Amsterdam on Monday, 20 April, 2009. Or visit the RainDance Technologies website at www.raindancetech.com, or call +44-786-3200-242.

For more information about the “Genomics in Business” conference, visit www.genomicsinbusiness2009.com.

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit www.raindancetech.com.

RainStorm™ is a trademark of RainDance Technologies, Inc.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: RainDance Technologies, sequence enrichment, targeted sequencing, RDT 1000, DNA sequencing, PCR, Genomics in Business

Tags: DNA sequencing, Genomics in Business, PCR, RainDance Technologies, RDT 1000, sequence enrichment, targeted sequencing
Posted in Biosciences |

Thursday, March 26th, 2009

RainDance Technologies Announces First Commercial Shipment of RDT 1000, Sequence Enrichment Solution

– Delivery to Ontario Institute for Cancer Research –

LEXINGTON, MASSACHUSETTS, U.S.A., March 26, 2009 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the first commercial shipment of its RDT 1000 and Sequence Enrichment Solution. The shipment will be delivered to the Ontario Institute for Cancer Research in Canada (OICR), a new, innovative institute dedicated to research in the prevention, early detection, diagnosis and treatment of cancer.

OICR will use the RainDance solution – consisting of a RDT 1000, consumables kits, custom PCR primer libraries, and expert training – in its programs involving the discovery and validation of DNA sequence variants associated with cancers. The solution is designed to increase quality and efficiency of performing targeted sequencing on large sample numbers.

“We are looking forward to implementing the RainDance platform at OICR – and to the benefits that the RainDance solution will bring to our programs,” said John McPherson, Director of OICR’s Cancer Genomics Program. “We expect the RainDance solution to become a critical element in accelerating the research phase of our studies that will ultimately result in our understanding of cancer.”

“The shipment to OICR represents a major milestone that exemplifies the power of the RainStorm™ microdroplet-based platform to those driving innovation in human health and disease research,” said Chris McNary, President and Chief Executive Officer of RainDance Technologies. “First, leading genome centers participating in the company’s Early Access Partner program have experienced the value of the RainDance solution. Now, our commercial platform is shipping and gaining acceptance in the rapidly growing sequence enrichment segment of the next-generation sequencing market.”

The RDT 1000 and Sequence Enrichment Solution utilize RainDance’s breakthrough RainStorm™ microdroplet-based technology platform. The simplicity and speed of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrichment Solution utilizes a library of PCR primers in droplets enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance’s solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.

“All of us at RainDance are grateful for the opportunity to support OICR — one of the world’s leading centers of cancer research — in its mission to advance human health,” McNary said.

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm™ technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance was founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

RainStorm™ is a trademark of RainDance Technologies, Inc.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/
bookmark to del.icio.us

Technorati tags: RainDance Technologies, sequence enrichment, targeted sequencing, RDT 1000, DNA sequencing, PCR

Tags: DNA sequencing, PCR, RainDance Technologies, RDT 1000, sequence enrichment, targeted sequencing
Posted in Biosciences |

Industry PR is proudly powered by WordPress.

About Tiziani Whitmyre

Tiziani Whitmyre Inc.'s public relations expertise is in technology & life sciences PR. We work with companies from small business startups to global leaders. Unlike traditional firms, we are very flexible in our PR services and combine the expertise of large agency professional talent within the flexibility of a boutique. We help clients generate sales leads, launch new products, enter new markets, establish technical leadership, and achieve other business goals. We craft and execute cost-effective, results-focused efforts that integrate traditional and Web 2.0 solutions as discrete projects, targeted campaigns, on-going PR programs, or elements in an integrated marketing program. Our industry experience is deep and includes analytical instruments, biotechnology, ecommerce, food and dairy, healthcare, high technology, laboratory sciences, life sciences, machinery, manufacturing, medical products, pharmaceuticals, professional services, and software

Social Media

Technorati tags: For Immediate Release, News Release, Press Release, Press Release News, PR, Public Relations, Tiziani Whitmyre, Biosciences News, Business News, Health News, Medical News, Hearing Protection News, Manufacturing News, Technology News, Boston

Posts Tagged ‘sequence enrichment’

About RainDance Technologies, Inc.

About RainDance Technologies, Inc.

About Tiziani Whitmyre

Links

Social Media